BridgeBio Pharma (BBIO) Capital Expenditures Growth (1y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 143.40% |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -79.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.53% |
| Dec 31, 2025 | 2,208.51% |
| Sep 30, 2025 | -171.32% |
| Mar 31, 2025 | 381.43% |
| Dec 31, 2024 | -89.20% |
| Sep 30, 2024 | 10.27% |
| Mar 31, 2024 | 483.33% |
| Dec 31, 2023 | 3,446.15% |
| Sep 30, 2023 | 5,792.31% |
| Jun 30, 2023 | 115.14% |
| Mar 31, 2023 | -98.60% |
| Dec 31, 2022 | -100.51% |
| Sep 30, 2022 | -100.20% |
| Jun 30, 2022 | -134.37% |
| Mar 31, 2022 | -56.20% |
| Dec 31, 2021 | 159.38% |
| Sep 30, 2021 | 1,077.05% |
| Jun 30, 2021 | 560.98% |
| Mar 31, 2021 | -56.20% |
| Dec 31, 2020 | -344.48% |
| Sep 30, 2020 | 44.09% |
| Jun 30, 2020 | 316.87% |
| Mar 31, 2020 | 948.48% |
| Dec 31, 2019 | 135.76% |
| Sep 30, 2019 | -37.02% |